EGFR and lung adenocarcinoma: A PDX model was established from an advanced‐stage EGFR‐mutated (L858R+T790M+MET amplification) lung adenocarcinoma patient that had progressed following resistance to both 2nd generation TKI (afatinib) and 3rd generation TKI (osimertinib).